First oral advanced therapy approved for moderate-to-severe Crohn’s disease

摘要

The first oral advanced therapy for adults with moderate to severely active Crohn’sdisease has been approved by the Medicines and Healthcare products RegulatoryAgency (MHRA). The approval of upadacitinib (Rinvoq; AbbVie) marks the first marketing authorisationglobally for the use of the Janus kinase (JAK) inhibitor in the treatment of the condition.